The enzyme serine hydroxymethyltransferse (SHMT) converts serine into glycine and a tetrahydrofolate-bound one-carbon unit. Folate one-carbon units support purine and thymidine synthesis, and thus cell growth. Mammals have both cytosolic SHMT1 and mitochondrial SHMT2, with the mitochondrial isozyme strongly up-regulated in cancer. Here we show genetically that dual SHMT1/2 knockout blocks HCT-116 colon cancer tumor xenograft formation. Building from a pyrazolopyran scaffold that inhibits plant SHMT, we identify small-molecule dual inhibitors of human SHMT1/2 (biochemical IC 50 ∼ 10 nM). Metabolomics and isotope tracer studies demonstrate effective cellular target engagement. A cancer cell-line screen revealed that B-cell lines are particularly sensitive to SHMT inhibition. The one-carbon donor formate generally rescues cells from SHMT inhibition, but paradoxically increases the inhibitor's cytotoxicity in diffuse large B-cell lymphoma (DLBCL). We show that this effect is rooted in defective glycine uptake in DLBCL cell lines, rendering them uniquely dependent upon SHMT enzymatic activity to meet glycine demand. Thus, defective glycine import is a targetable metabolic deficiency of DLBCL.
The enzyme serine hydroxymethyltransferse (SHMT) converts serine into glycine and a tetrahydrofolate-bound one-carbon unit. Folate one-carbon units support purine and thymidine synthesis, and thus cell growth. Mammals have both cytosolic SHMT1 and mitochondrial SHMT2, with the mitochondrial isozyme strongly up-regulated in cancer. Here we show genetically that dual SHMT1/2 knockout blocks HCT-116 colon cancer tumor xenograft formation. Building from a pyrazolopyran scaffold that inhibits plant SHMT, we identify small-molecule dual inhibitors of human SHMT1/2 (biochemical IC 50 ∼ 10 nM). Metabolomics and isotope tracer studies demonstrate effective cellular target engagement. A cancer cell-line screen revealed that B-cell lines are particularly sensitive to SHMT inhibition. The one-carbon donor formate generally rescues cells from SHMT inhibition, but paradoxically increases the inhibitor's cytotoxicity in diffuse large B-cell lymphoma (DLBCL). We show that this effect is rooted in defective glycine uptake in DLBCL cell lines, rendering them uniquely dependent upon SHMT enzymatic activity to meet glycine demand. Thus, defective glycine import is a targetable metabolic deficiency of DLBCL.
SHMT | cancer metabolism | glycine | DLBCL | folate C ancer growth and proliferation are supported by metabolic changes, including enhanced glucose uptake, aerobic glycolysis (the Warburg effect), and folate-dependent one-carbon (1C) metabolism (1, 2) . The predominant source of 1C units in cancer cells is the amino acid serine (3) . The enzyme serine hydroxymethyltransferase (SHMT) catalyzes the conversion of serine and tetrahydrofolate (THF) into glycine and 5,10-methylene-THF. Increases in the synthesis and consumption of serine and glycine have been identified in transformed cells and cancers (4) (5) (6) . Mitochondrial SHMT (SHMT2) and the immediately downstream mitochondrial enzyme 5,10-methylene-tetrahydrofolate dehydrogenase (MTHFD2) are the most consistently overexpressed metabolic enzymes in cancer (7) (8) (9) (Fig. 1A) . In most rapidly proliferating cells, 1C units generated from serine catabolism in the mitochondria are exported to the cytosol as formate, which is then reassimilated into folates to support nucleotide synthesis (10) (11) (12) .
While the mitochondrial pathway typically supplies all of the 1C units in proliferating cells in culture, it is not essential in nutrient replete conditions, as evidenced by the viability of SHMT2 and MTHFD2 deletion cell lines (11, 13) . In such deletion cells, cytosolic SHMT1 now metabolizes serine to produce 1C units required for purine and thymidine synthesis. However, the flux carried through this enzyme is insufficient to meet glycine demand, and mitochondrial folate-mutant cell lines are glycine auxotrophs (14) . Because glycine is abundant in serum, such auxotrophy has not been considered physiologically relevant in mammals. However, recent work has identified functional amino acid shortages in human tumors, suggesting that transport from serum to tumor may be limiting in some contexts, resulting in dependence on intracellular synthesis (15) .
One-carbon metabolism is targeted therapeutically by multiple existing drugs, including the common clinical agents pemetrexed, 5-fluorouracil, and methotrexate (16) . One mechanism of action common to several of these agents is inhibition of thymidylate synthase, which utilizes 5,10-methylene-THF. While new chemical tools have recently been disclosed that block de novo serine synthesis (17) (18) (19) , no existing chemotherapies specifically target the production of 1C units from serine, the primary source of 1C units in tumors.
To block the production of 1C units from serine, simultaneous inhibition of both the cytosolic SHMT1 and mitochondrial SHMT2 is necessary. Here we genetically validate that dual SHMT1/2 genetic knockout, in Ras-driven colon cancer cells, prevents xenograft formation. We present the development of a low nanomolar, stereospecific small-molecule inhibitor of human SHMT1/2. Dual SHMT inhibition blocks growth of many cell lines in a manner that is rescued by the soluble 1C donor formate. In diffuse large B-cell lymphoma (DLBCL) cell lines, however, formate does not rescue cell growth but instead paradoxically enhances cancer cell death. We find that this unexpected outcome reflects a previously unappreciated biochemical vulnerability of DLBCL: inability of these cells to
Significance
Enzymes of the folate cycle are among the most consistently overexpressed proteins in cancer. Whereas multiple clinical agents inhibit thymidylate synthase, no current drugs target the incorporation of one-carbon into folates via serine hydroxymethyltransferase (SHMT). Using genetics, we show that cancer cells require SHMT to generate tumors. We then describe smallmolecule SHMT inhibitors, and show that they block the growth of many human cancer cells, with B-cell lymphomas particularly sensitive to SHMT inhibition. We find that this sensitivity arises from the lymphomas' inability to import the amino acid glycine, which is made as a byproduct of the SHMT reaction. Thus, B-cell lymphomas have an intrinsic defect in amino acid import, which causes a therapeutically targetable metabolic vulnerability. take up glycine, which was previously viewed as a nonessential byproduct of the SHMT reaction.
Results
Requirement for SHMT Activity in HCT-116 Xenograft Formation. We generated clonal deletion cell lines of SHMT1, SHMT2, and SHMT1/ 2 from the human colorectal carcinoma cell line HCT-116. Paired Cas9 nickase (Cas9n)-containing constructs that encoded single-guide RNA sequences targeting SHMT1 or -2 were transiently transfected into cells, and mutant colonies from single clones were picked as previously described (11) . As previously reported, SHMT1 deletion had no effect on cell growth either in cell culture or as subcutaneous xenografts in nude mice. In contrast, SHMT2 deletion cells grew slower in culture and as xenografts (Fig. 1B and Fig. S1A ). Liquid chromatography-mass spectrometry (LC-MS) analysis of the soluble metabolites extracted from SHMT2 deletion tumors revealed characteristic signs of defective serine catabolism (Fig. S1B ): serine levels were increased ∼twofold and the purine intermediate aminoimidazole carboxamide ribotide (AICAR), whose consumption requires 10-formyl-THF, was elevated ∼25-fold.
To generate dual SHMT1/SHMT2 double-deletion cell lines, SHMT2 deletion cells were transfected with Cas9 and guide RNA sequences targeting SHMT1 in the presence of 1 mM sodium formate. Isolated clones cultured in formate grew at rates comparable to WT parental cells; no growth was observed in media without formate (Fig. S1 C and D) . To test whether circulating nucleotides and 1C sources in vivo could support the growth of SHMT1/SHMT2 double-deletion cells, we xenografted them into nude mice. No tumors were observed from the SHMT1/SHMT2 double-deletion cells (Fig. 1C and Fig. S1E ). Thus, in HCT-116 xenografts, circulating alternative 1C donors (e.g., betaine, sarcosine, formate) and nucleotides are together insufficient to support intracellular 1C metabolism required for tumorigenesis. It remains to be tested whether SHMT activity is essential for tumors derived from other cell lineages, or whether differential requirements might exist for tumorigenesis versus maintenance.
Small-Molecule Inhibitors of Human SHMT1/2. Compounds with the pyrazolopyran scaffold represented by compound 1 ( Fig. 2A) were described as inhibitors of plant SHMT and showed efficacy as herbicides (20) . Derivatives with a meta-thiophene substitution were recently published as inhibitors of Plasmodium SHMT (21) . When these compounds were tested in human cell culture, potency was poor (22) . We optimized compounds of this class for human SHMT1 and 2 (23) . Compounds of this class were modestly more potent in vitro against SHMT1 than SHMT2. Changes that improve potency against both human isoforms include introduction of an isopropyl group at the chiral four-carbon of the pyrano ring and adding steric bulk to the metasubstitutions on the phenyl ring (compound 2). Aromatic substitution at this position further increased potency, yielding compound 3, which inhibits T cell proliferation (24) . We term this inhibitor serine hydroxymethyltranferase inhibitor 1, or SHIN1.
To understand the binding mode of these inhibitors, we solved a 2.47-Å structure of human SHMT2 as a dimer in complex with glycine, pyridoxal 5′-phosphate (PLP), and racemic compound 2 ( Fig. 2B and Table S1 ) (PDB ID code 5V7I). Electron density was identified in both binding pockets of the protein dimer, but in only one active site was it well resolved. Similar to the solved structure of a pyrazolopyran inhibitor in complex with Plasmodium vivax SHMT (21), hydrogen binding contacts with the exocyclic amine are made with the amide backbone of L166 and between the pyrazole and H171. Overlaying our inhibitor-bound structure with a previously solved structure of rabbit SHMT1 bound to 5-formyl-THF triglutamate (PDB ID code 1LS3) revealed that the bicyclic ring system of compound 2 and pteridine moiety of folate occupy the same space, but at a different angle (Fig. 2B) . However, hydrogen bond contacts are preserved, and engage the inhibitor at several core positions, including the exocyclic amine and the pyrazole nitrogens. The substituted phenyl ring and associated pyrrolidine of compound 2 trace along the para-aminobenzoic acid moiety of folate as it exits the pteridine binding pocket toward the solvent-exposed folate polyglutamate side chain. Directly adjacent to the pyrrolidine lies a tyrosine residue that is well positioned to form a π-stacking interaction with the phenyl of SHIN1, potentially contributing the improved potency of this compound. Given the conserved nature of the SHMT active site, these compounds are likely to inhibit SHMT enzymes not only of humans, but also other mammals.
Both compound 2 and SHIN1 contain a single chiral center. Although crystallization was performed with racemic compound 2, the electron density was consistent with only a single enantiomer binding to the enzyme. Using chiral chromatography, we separated compound 2 and confirmed enantioselective enzyme inhibition (Fig. S2A) .
Cell Growth Inhibition. We next sought to investigate the activity of compound 2 and SHIN1 against cytosolic and mitochondrial SHMT isoforms in cultured cells. The inactive (−) enantiomer of SHIN1 had no significant effect on growth in HCT-116 cells at doses up to 30 μM (Fig. S2B) , whereas the active (+) enantiomer blocked growth with half-maximal inhibitory constants (IC 50 ) of 870 nM ( Fig.  2 C and D) . To analyze the effects of inhibition on each isoform independently, we used the SHMT1 and SHMT2 HCT-116 deletion clones. The active enantiomers of both compounds, (+)-2 and (+)-SHIN1, were potent against cytosolic SHMT1, as evidenced by IC 50 for growth of less than 50 nM in SHMT2 deletion cells ( Fig.  2 C and D) . In contrast, SHMT1 deletion cells showed indistinguishable sensitivity from WT, confirming that mitochondrial SHMT inhibition is limiting for compound efficacy (Fig. 2D ).
As compound 2 and SHIN1 both have similar biochemical activities against SHMT1 and SHMT2, the much higher doses required for functional inhibition of cellular SHMT2 likely reflects a combination of imperfect mitochondrial penetration and greater intrinsic cellular SHMT2 activity (i.e., a substantial functional reserve due to high SHMT2 expression). Importantly, the effects on cell growth of compound 2 and SHIN1 could be rescued by addition of formate, indicating that they inhibit cell growth through on-target depletion of cellular 1C pools (Fig. 2D) . However, because glycine is also a product of the SHMT reaction, formate can only rescue cell growth when this amino acid is present in the media (Fig. S2C) .
Notably, while most cancers have high mitochondrial 1C pathway activity, certain cancer cells, such as the pancreatic cancer cell line 8988T, harbor genetic lesions in the mitochondrial folate pathway activity and therefore rely on SHMT1 to generate 1C units (11) . In such cells, SHIN1 impairs cell growth at concentrations <100 nm due to its potent engagement of cellular SHMT1 (Fig. S2D) .
SHMT Target Engagement. Inhibition of cellular SHMT activity can be monitored by isotope tracers and LC-MS. U- 13 C serine is catabolized in the mitochondria by SHMT2 into U- 13 C-glycine and a 13 C-5,10-methylene-THF. Glycine is further incorporated into downstream metabolites, such as glutathione and purines, whereas the folate 1C unit can be exported to the cytosol for incorporation into purines and thymidine. In addition, glycine and a 1C unit can recombine to make partially labeled serine via SHMT1 or SHMT2 (Fig. S3A) . To assess target engagement, we compared the effects of SHMT genetic manipulations to pharmacological treatment with SHIN1. Serine media consumption was inhibited in both HCT-116 SHMT1/2 double-deletion cells and WT cells treated with (+)-SHIN1 (Fig. S3B) . Glycine production from serine and subsequent incorporation into glutathione or ADP was completely blocked in SHMT1/2 double-deletion cells, as evidenced by the missing M+2 labeling fraction (Fig. 3A) . Nearly complete blockade was observed in WT cells treated with (+)-SHIN1 but not the inactive enantiomer (−)-SHIN1. Drug treatment also blocked recombination of glycine and 10-formyl-THF to reform serine (Fig. S3B) . Genetic deletion of SHMT1/2, and to a lesser extent SHMT2, results in a build-up of purine biosynthetic intermediates upstream of steps requiring 10-formyl-THF as a substrate (Fig.  3B) . Such build-up is also seen with (+)-SHIN1. Thus, SHIN1 phenocopies-in an enantioselective manner-the metabolic consequences of SHMT genetic deletion.
To assess the selectivity of the metabolic effects of SHIN1, we performed untargeted LC-MS analysis on soluble metabolites from drug-treated cells (Fig. 3C) . In addition to purine intermediates, we saw build-up of purine salvage products (xanthosine, guanosine), whose increase is consistent with purine insufficiency. We further saw build-up of homocysteine, a classic marker of 1C deficiency. We also observed depletion of the pyrimidine intermediate N-carbamoyl-aspartate, likely reflecting feedback inhibition of aspartate transcarbamoylase by excess pyrimidines in the purine-starved cells (25) . Importantly, there were no other large changes in metabolism, suggestive of off-target effects. Moreover, the changes in abundances were rescued by formate (Fig. 3D ) and metabolite abundances in SHMT1/2 double-deletion cells closely matched those from WT cells treated with (+)-SHIN1 (Fig. S3C) . Thus, at doses sufficient to robustly inhibit SHMT1 and SHMT2 in cell culture, (+)-SHIN1 selectively targets 1C metabolism.
Cancer Cell Line Sensitivity to SHMT Inhibition. Unfortunately, SHIN1 and related pyrazolopyrans are unstable in liver microsome assays and have poor in vivo half-lives, precluding their immediate use in animal models. Accordingly, we focused on their in vitro application across a wide range of cancer cell lines. Specifically, we screened a panel of nearly 300 human cancer cell lines for growth in the presence of the (+)-enantiomer of compound 2 ( Fig. 4A and Table S2 ). The median IC 50 was 4 μM. Cell lines of B-cell lymphoma origin were enriched in the more sensitive half of cells (P < 0.001, Fisher's exact test). This effect was driven by a pronounced sensitivity of Burkitt's and DLBCL lymphomas (Fig. 4A) . We then rescreened a set of hematological cancer lines with (+)-SHIN1, supplemented with and without formate to test for rescue (Fig. 4B) . Like HCT-116 cells, cell lines of T cell origin, such as acute lymphocytic leukemia (ALL) cells, were largely rescued from the antigrowth effects of (+)-SHIN1 by formate (Fig. 4B, gray bars) . In contrast, formate failed to rescue the growth of B-cell lymphoma lines.
To explore this surprising lack of rescue further, we analyzed by flow cytometry the effect of (+)-SHIN1, with and without formate, on the DLBCL cell line Su-DHL-4. SHIN1 itself induced apoptosis as measured by Annexin V surface staining (Fig.  4C and Fig. S4A ). Apoptosis was enhanced by cotreatment with formate. In contrast, as expected, formate rescued Jurkat E6-1 leukemia cells from apoptosis ( Fig. 4C and Fig. S4B ).
To account for these observations, we hypothesize that the failure of formate to rescue growth in the DLBCL cell lines is due to a requirement for both glycine and 1C units made by SHMT in these cells. When glycine is limiting, formate can enhance the cytotoxicity of SHMT inhibition. For example, formate augments the effect of SHIN1 in HCT-116 cells in glycine-free media (Fig. S2C) . Mechanistically, by supplying 5,10-methylene-THF, formate may drive residual SHMT enzymatic function in the glycine-consuming direction. Alternatively, whereas cells may have the machinery to sense 1C deficiency and safely pause growth (e.g., due to AICAR activation of AMPK), they may lack comparable mechanisms for surviving glycine limitation.
DLBCL Cells Require SHMT to Make Glycine for Purine Synthesis. The inability of formate to rescue the antigrowth effects of SHIN1 in DLBCL cell lines suggested that glycine may be limiting in these cells. To explore this hypothesis, we characterized the metabolic effects of SHIN1 in DLBCL and Jurkat cells treated with (+)-SHIN1 (72 h, 5 μM) with and without formate. In Jurkat and DLBCL cell lines Su-DHL-4 and Su-DHL-2 in the absence of formate, SHIN1 treatment led to a large reduction in nucleotide triphosphates ( Fig.  5A and Fig. S5A ). This can be rationalized as reflecting impaired purine synthesis, which requires both 1C units and glycine, with pyrimidines also falling due to endogenous mechanisms that balance their levels with those of purines. There is also a component of energy stress, particularly in Su-DHL-4 cells, as nucleotide monophosphates were increased, not decreased (Fig. S5B) . Consistent with 1C limitation, dTTP, whose synthesis requires a folate 1C unit, was more depleted than other pyrimidines.
Formate supplementation restored nucleotide levels in Jurkat but not DLBCL cell lines. We confirmed that formate rescues folate 1C levels in DLBCL cells, as the AICAR accumulation induced by (+)-SHIN1 is fully reversed (Fig. S5C) . Thus, while nucleotide synthesis in SHIN1-treated Jurkat cells is solely limited by 1C units, an additional factor is lacking in DLBCL cells. Consistent with glycine being the second factor missing in DLBCL cells, (+)-SHIN1 treatment depleted the glycine-containing redox defense tripeptide glutathione (Fig. 5B and Fig. S5D ). Strikingly, while SHIN1 alone did not alter glutathione in Jurkat cells, formate addition caused glutathione depletion. This further validates that, when SHMT is inhibited, provision of excess 1C units can cause glycine stress. Glutathione supplementation did not rescue growth (Fig. S5E) . Based on these results, we predicted that growth in SHMT-inhibited DLBCL cells might be restored with purine supplementation, which would simultaneously alleviate 1C and glycine metabolic stress. Growth was partially rescued in Su-DHL-4 cells treated with hypoxanthine (Fig. 5C) . Thymidine, which rescues the effects of the classic antifolate pemetrexed but does not contain glycine, had no benefit in SHIN1-treated DLBCL cells. Thus, SHIN1 blocks cell growth through a progressive depletion of purines, leading to loss of nucleotide triphosphates. Restoration of purines levels restores growth.
The depletion of glycine-derived metabolites in DLBCL cells led us to examine whether glycine shortage might also impact protein synthesis. Severe amino acid shortages lead to loss of cognate tRNA charging and thus ribosome stalling, which can be measured using ribosome profiling (15) . We performed ribosome profiling on Su-DHL-4 cells treated with (+)-SHIN1 (Fig. S6 A  and B) . Untreated Su-DHL-4 cells growing in RPMI did not show evidence of glycyl-tRNA insufficiency; no enrichment for these codons was observed (Fig. S6C) . Furthermore, we did not observe any difference in glycine codon occupancy between treated and control cells (Fig. S6D) . Collectively, these results suggest a hierarchy in the sensitivity of different intracellular metabolic products to glycine levels: glutathione synthesis is most sensitive, μM respectively) as indicated by flow cytometry using FITC-Annexin V staining (mean ± SD, n ≥ 3, *P < 0.05, ***P < 0.001, unpaired t test).
followed by purine synthesis, with protein synthesis most resistant. This hierarchy is consistent with biochemical measurements of the K m values of the relevant enzymes: the glycyl-tRNA amino acid synthase has a lower K m for glycine (15 μM) than that found in glycinamide ribonucleotide synthetase (45 μM) or glutathione synthetase (452 μM) (26) (27) (28) .
Defective Glycine Uptake in DLBCL. SHIN1 induced glycine deficiency in DLBCL cells, even though they were cultured in complete media with glycine (RPMI, 10 mg/L glycine = 130 μM). This suggested that glycine uptake is intrinsically impaired in these cells. Using U-
13
C-glycine, we monitored the kinetics of extracellular glycine incorporation into cells and downstream metabolic products (Fig. 5D) . Labeling of intracellular glycine products, such as glutathione and ADP, was markedly less in Su-DHL-4 cells than Jurkat cells. In a larger set of cell lines, composed of both other hematological cancer and adherent cell lines, steady-state labeling of intracellular metabolites from glycine was significantly lower in B-cell lymphoma cell lines (Fig. 5E) .
Given the apparent glycine shortage in these B cells upon SHIN1 treatment, we next sought to augment extracellular glycine levels and evaluate response to drug. We first altered the concentration of glycine in RPMI and observed response to drug. A reduction of glycine in the media modestly improved the potency of SHIN1, indicating that the cells were sensitive to extracellular glycine. More strikingly, increasing the media glycine by 10-fold substantially rescued the cells from SHIN1 (Fig. S5F) . In contrast, in Jurkat cells, a small amount of extracellular glycine was sufficient and more did not further rescue the cells from SHIN1 (Fig. S5G) . Across a set of DLBCL cell lines, representing both ABC and GBC subtypes, supplying both formate and supraphysiologic glycine (100 mg/L, 1.3 mM) generally rescued cell growth (Fig. 5F ). These results indicate the importance of both products of the SHMT reaction, glycine and folate 1C units, for the proliferation of DLBCL cell lines.
Knowing that manipulating glycine could augment the efficacy of SHIN1, we tested different mechanisms to decrease glycine. As observed previously, when formate was added, SHIN1 was transformed from being a drug that slowed cell growth to one that was fully cytostatic (Fig. 5G) . Further removing glycine caused significant cell death. Interestingly, combining the glycine reuptake transporter 1 (GlyT1; SLC6A9) inhibitor RG1678 with SHIN1 further increased cell death, even in the presence of media glycine (29) (Fig. 5G) . These results suggest that glycine uptake in these cells is mediated by GLYT1 and that combinations of formate, SHMT inhibitor, and GLYT1 inhibitor may selectively target these cells.
Discussion
Targeting folate metabolism has been employed clinically to treat cancer for over 70 y (30) . Despite the use of antifolates and other antimetabolites in many important chemotherapy regimens, their clinical effectiveness is limited by side effects in normal proliferating tissue. Identifying metabolic processes that can be targeted in a more tumor-selective manner remains a major challenge. C-glycine (mean ± SD, n = 3). (F) Cell growth (normalized to DMSO) of DLBCL and other hematopoietic cancer lines with 2.5 μM SHIN1, in RPMI with or without 1 mM formate and 10× physiological glycine (100 mg/L); all conditions included at least normal media glycine (10 mg/L; mean ± SD, n = 3). (G) Cell growth (or death) as measured by log 2 -fold change in cell number over 48 h in Su-DHL-4 cells cultured in RPMI with and without glycine (10 mg/L), formate (1 mM), the glycine transporter inhibitor RG1678 (300 nM), and/or (+)-SHIN1 (5 μM) (mean ± SD, n = 3). (H) Schematic illustrating the proposed glycine vulnerability in B cells. The SHMT reaction makes two products, 5,10-methylene-THF and glycine. When SHMT is inhibited, exogenous formate can be incorporated into the 1C cycle, whereas in B cells poor glycine uptake limits the ability of extracellular glycine to rescue.
In this study, we targeted the SHMT reaction, which uses serine to generate a folate-bound 1C unit and glycine. Consistent with prior reports (22), we found that pyrazolopyrans have detectable activity against human SHMT. Through substantial chemistry efforts, we enhanced the potency for human SHMT by over 100-fold, resulting in inhibitors such as SHIN1 with on-target dual SHMT1/ 2 cellular inhibition at nanomolar to low micromolar concentrations. We extensively validated the on-target activity of these compounds using metabolomics in combination with genetics. While these compounds have appropriate stability for cell culture studies, including of primary T cells (24), they are not currently usable in vivo due to rapid clearance.
Screening of cancer cell lines for sensitivity to small-molecule SHMT1/2 inhibitors revealed specific metabolic vulnerabilities of certain cancers. One mode of sensitization, exemplified by the pancreatic cancer cell line 8988T, results from defects in mitochondrial folate metabolism. Such cells are dependent upon SHMT1 for production of 1C units, and functionally have low reserve SHMT activity, rendering them sensitive to low concentrations of SHIN1.
By a different mechanism, B-cell lymphomas are also uniquely sensitive to SHMT inhibition. We show that these cells are intrinsically deficient in glycine uptake and thus require glycine made by SHMT to grow. When combined with formate, SHMT inhibitors do not function as classic antifolates by disrupting 1C metabolism, but rather, in cells with impaired glycine uptake, as cell-type-specific glycine depletion agents (Fig. 5H) . As a fundamental precursor to many essential biomolecules, glycine is in high demand. Indeed, the quantitative demand for glycine to support protein, nucleotide, and glutathione synthesis exceeds the cellular requirement for 1C units (11) . Using metabolomics and ribosome profiling, we characterized the susceptibility of these processes to glycine stress. Consistent with the reported enzymatic K m values, glutathione and purine synthesis were more sensitive than protein synthesis to glycine depletion.
Targeting an amino acid vulnerability is a well-established therapeutic strategy in cancer. A useful comparison with the intrinsic defect in glycine uptake in DLBCL is the defect in asparagine synthesis in ALL, which creates a dependence upon external sources of asparagine (31) . This dependence is targeted by asparaginase, a core medicine in pediatric ALL therapy (32) . In DLBCL, because the defect is in glycine transport rather than synthesis, the therapeutic strategy rests on inhibiting intracellular glycine synthesis. The resulting efficacy can be increased either by decreasing extracellular glycine, or more promisingly therapeutically, by further depleting intracellular glycine by formate addition or glycine uptake inhibition. Formate is attractive because it can rescue the effects of SHMT inhibition in normal tissues with strong glycine uptake. Both approaches however, may exacerbate toxicity in tissues with naturally low glycine transport. While glycine transport is poorly characterized in vivo in most tissues, existing data suggest immune and neurological tissues may be potentially sensitive to modulation of glycine synthesis. Going forward, a careful assessment of amino acid transport in vivo will be required to understand how to best exploit glycine transport defects for therapy.
Methods
All mouse work was approved by the Princeton University Institutional Animal Care and Use Committee. For metabolite measurements, cultured cells were incubated in media containing dialyzed FBS and the isotopically labeled metabolite of interest. Cells were quenched with cold methanol and metabolites analyzed by LCMS. Full-length human SHMT1 and -2 protein was isolated from Escherichia coli using nickel capture followed by cleavage of the HIS tag using tobacco etch virus (TEV) protease. Complete chemical synthesis details and compound characterizations are provided in Chemical Synthesis Methods. All experimental procedures are described in detail in SI Methods.
